Precision radiation targets prostate tumors with MRI guidance

NCT ID NCT06542757

Recruiting now Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new way to deliver radiation for intermediate-risk prostate cancer. Using an MRI machine that also delivers radiation, doctors can give a higher dose to the main tumor while lowering the dose to the rest of the prostate. The goal is to improve tumor control and reduce side effects. About 91 participants will be followed for two years to see if the tumor is gone on biopsy and to track any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (MR-guided ultra-hypofractionated external beam radiation with a dose boost to the dominant tumor)
What this could lead to: If successful, this approach could offer a more precise and effective radiation treatment for intermediate-risk prostate cancer, potentially reducing side effects and improving tumor control.
What could go wrong: This is a small, early-phase study (91 participants) with no control group, so results may not apply broadly. There are risks of radiation side effects, and the treatment may not improve outcomes over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERMEDIATE RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

NYU Langone Health
RECRUITING

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.